Guest: Harry Paul Erba, MD, PhD 


 Although survival among younger patients with acute myeloid leukemia (AML) has improved over the past decade, older patients continue to have a poor prognosis. And since age and frailty are the primary predictors of outcome among patients with AML, Dr. Harry Erba shares how the treatment of older patients with AML may be changing. BCL2-US-00027-MC Version 2.0, Approved November 2020

Guest: Harry Paul Erba, MD, PhD Although survival among younger patients with acute myeloid leukemia (AML) has improved over the past decade, older patients continue to have a poor prognosis. And since age and frailty are the primary predictors of outcome among patients with AML, Dr. Harry Erba shares how the treatment of older patients with AML may be changing. BCL2-US-00027-MCVersion 2.0, Approved November 2020

Guest: Harry Paul Erba, MD, PhD 


 Although survival among younger patients with acute myeloid leukemia (AML) has improved over the past decade, older patients continue to have a poor prognosis. And since age and frailty are the primary predictors of outcome among patients with AML, Dr. Harry Erba shares how the treatment of older patients with AML may be changing. BCL2-US-00027-MC Version 2.0, Approved November 2020

Changing Our View of Acute Myeloid Leukemia in Older Adults

This unique series features the latest developments in medicine, science, and technology produced in conjunction with our sponsors, who are dedicated to bringing healthcare providers lively discussions with experts from around the country. Tune in each week to hear the latest podcasts from ReachMD's "Spotlight On" series.

Share Changing Our View of Acute Myeloid Leukemia in Older Adults

Sign up to save your podcasts

Changing Our View of Acute Myeloid Leukemia in Older Adults

Changing Our View of Acute Myeloid Leukemia in Older Adults